^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    telatinib (BAY 57- 9352)

    i
    Other names: BAY 57- 9352, EOC315, TEL0805
    Associations

    News

    Trials
    Company:
    EddingPharm
    Drug class:
    c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=17, Active, not recruiting, Andrew Hendifar, MD | Trial completion date: Feb 2024 --> Feb 2025
    Trial completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • telatinib (BAY 57- 9352)
    1year
    Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=17, Active, not recruiting, Andrew Hendifar, MD | Recruiting --> Active, not recruiting | N=45 --> 17
    Enrollment closed • Enrollment change • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • telatinib (BAY 57- 9352)
    almost2years
    Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=45, Recruiting, Andrew Hendifar, MD | Active, not recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • telatinib (BAY 57- 9352)
    2years
    Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=45, Active, not recruiting, Andrew Hendifar, MD | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • telatinib (BAY 57- 9352)
    almost3years
    Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=45, Recruiting, Andrew Hendifar, MD | Not yet recruiting --> Recruiting | Trial completion date: Nov 2023 --> Feb 2024 | Initiation date: May 2021 --> Aug 2021 | Trial primary completion date: Nov 2023 --> Feb 2024
    Clinical • Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • telatinib (BAY 57- 9352)
    3years
    Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=45, Not yet recruiting, Andrew Hendifar, MD
    Clinical • New P2 trial • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • telatinib (BAY 57- 9352)